Patent · US Expired

Hemoglobins with intersubunit desulfide bonds

US5449759A · kind A · utility

27Cited by
18References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 29, 1993
Grant dateSep 12, 1995
Priority date
Expiry dateNov 29, 2013

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Cysteine substitution mutants of alpha and/or beta globin mutants are produced by recombinant DNA techniques and used in the construction, intracellularly or otherwise, of mutant hemoglobins in which alpha- and beta-globin like subunits are crosslinked by disulfide bonds. Solutions of these mutant hemoglobins are used as blood substitutes. Preferably, these mutant hemoglobins contain further mutations which reduce their affinity for oxygen. Hemoglobins are preferably obtained by recombinant DNA techniques. Both alpha and beta globin chains can now be readily expressed, making possible the commercial production of wholly artificial hemoglobin, whether conventional or mutant in form. Solutions of wholly artificial hemoglobins are also used as blood substitutes. Expression of the alpha globin gene was substantially improved by means of a beta globin gene "header".

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.